Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note published on Monday morning. The brokerage issued a sell rating on the stock.

A number of other brokerages have also recently weighed in on SYRS. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating and issued a $1.00 target price (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Syros Pharmaceuticals has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Price Performance

SYRS stock opened at $0.20 on Monday. The business has a 50 day moving average price of $1.13 and a 200 day moving average price of $2.82. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. The stock has a market cap of $5.47 million, a price-to-earnings ratio of -0.07 and a beta of 1.34. Syros Pharmaceuticals has a fifty-two week low of $0.18 and a fifty-two week high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter last year, the firm posted ($1.35) EPS. Equities research analysts anticipate that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

Insider Activity

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of Syros Pharmaceuticals stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the transaction, the director now directly owns 41,070 shares in the company, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 12.26% of the company’s stock.

Institutional Investors Weigh In On Syros Pharmaceuticals

Several hedge funds have recently modified their holdings of SYRS. Exome Asset Management LLC increased its stake in Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after buying an additional 139,400 shares during the period. Certuity LLC purchased a new stake in shares of Syros Pharmaceuticals in the second quarter valued at about $109,000. Acadian Asset Management LLC increased its stake in shares of Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after acquiring an additional 17,416 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Syros Pharmaceuticals during the third quarter worth about $34,000. 91.47% of the stock is owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.